European Association of E-Pharmacies (EAEP): EAEP as a Driving Force and Think Tank: European Association of Online Pharmacies Repositions Itself
(Brussels/Berlin): – The leading association of European online pharmacies has a new board team, a new name and a new external image:
Walter Hess, Head Germany in the Group Management of the Zur Rose Group and CEO of DocMorris N.V., is now president of the association and Stefan Feltens, CEO SHOP APOTHEKE EUROPE, is vice president and secretary general. With the new leadership duo, the association of online pharmacies will shape the European healthcare sector’s digital transformation in a future-oriented way. A key goal is to further expand the practical patient benefits of online pharmacies in the implementation of future e-health concepts. Vladimir Finsterle, CEO and founder of Pearls Health Cyber s.r.o., and Gianni De Gaspari, CEO and co-founder of the online pharmacy Viata, complete the board.
By changing its name from EAMSP (European Association of Mail Service Pharmacies) to EAEP (European Association of E-Pharmacies), the association underlines its key role in Europe’s increasingly digitised healthcare systems. As online pharmacies, the EAEP’s long-standing members ensure that people all over Europe have optimal access to medicines and pharmaceutical advice every single day. Accordingly, the new logo symbolises the connection between people and pharmacies.
"With Walter Hess, the EAEP gains an experienced market expert as president," says Stefan Feltens. "Together we will demonstrate that the members of the EAEP have systemically relevant answers to changing customer needs and market conditions. To ensure this, we will continue and further intensify our dialogue with politics, society and the economy. We see ourselves as a driving force and use our digital skills for the benefit of consumers.
"As a leadership duo, we want to help shape the future of the healthcare system. We see the EAEP as a European think tank for e-health issues. As pioneers in the European pharmacy market, we will leverage digital solutions to contribute to advancing access, safety, quality, service and sustainability in healthcare in the interest of consumers across Europe," emphasises Walter Hess.
The new website www.eaep.com gives the association a contemporary web presence that describes its services and positions and provides a wide range of information on the European health market, from statements on legislation to electronic prescriptions.
Profile: The European Association of E-Pharmacies (EAEP) represents the interests of its members and protects the needs of its members' patients and customers. It informs the public in a transparent manner, enters into a dialogue with politics, the economy and market partners, and contributes its concepts to strengthen the European health sector and to enable cost reductions through digitisation.
The members of the EAEP are pioneers in digital solutions designed to continuously improve the quality, safety and efficiency of healthcare for people across Europe. The association bundles the voices of its members in position papers and promotes interaction and knowledge exchange.
Contacts
EAEP
Avenue Marnix 28
B-1000 Ixelles / Brussels
Belgium
About news aktuell GmbH
news aktuell, a subsidiary of the Deutsche Presse-Agentur (dpa), provides companies, institutions and associations with effective access to both the media and consumers and supports the organizations in telling their stories easily and successfully. Utilizing the digital tools “ots” and “zimpel” PR content reaches all media formats, including classic print titles, wide-reach online portals or social networks. In addition, news aktuell publishes all of its clients' PR content on www.presseportal.de, one of Germany's widest-reaching PR portals. Thus, all relevant multipliers are reached worldwide, ranging from editors and digital influencers to specialist bloggers and interested consumers. Communications specialists from all over Germany rely on the expertise of the dpa subsidiary. news aktuell has been on the market since 1989 and employs over 135 people. The company is based in Hamburg. Further locations include Berlin, Frankfurt and Munich.
Subscribe to releases from news aktuell GmbH
Subscribe to all the latest releases from news aktuell GmbH by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from news aktuell GmbH
Vyoma’s first Space Domain Awareness satellite has reached orbit13.1.2026 13:42:00 CET | Press release
Munich, 13. January 2026 - Vyoma, a Germany-based company providing Space Domain Awareness (SDA) capabilities, has launched its pioneering surveillance satellite, Flamingo-1, on Sunday, January 11th, 2026 from Vandenberg Space Force Base, California, USA. It was launched aboard the Twilight rideshare mission with SpaceX via Germany-based launch integrator Exolaunch. The satellite was deployed to its operational Sun-synchronous orbit of approximately 500-km in altitude. This marks a significant achievement for the company, which patented the operational concept of an optimized SDA mission. Flamingo-1, equipped with an optical sensor for space-based space surveillance, is a gamechanger for Europe, strengthening SDA efforts directly from orbit. The advanced optical instrument will detect, track and characterize space objects, such as debris and other satellites. Crucially, it will allow Vyoma and its customers to follow up on manoeuvring objects and derive insights into adversary actions
ORTEC expands German healthcare footprint with strategic acquisition of Klages & Partner13.1.2026 09:00:00 CET | Press release
Acquisition adds over 200 healthcare customers and sector-specific workforce management expertise to ORTEC’s portfolio
Acousia Announces Completion of Patient Enrollment in Phase 2 PROHEAR Study Evaluating ACOU085 (INN: Bimokalner) for the Prevention of Cisplatin-Induced Ototoxicity8.1.2026 09:00:00 CET | Press release
Tübingen, Germany, January 8, 2026 Acousia Therapeutics GmbH, a clinical-stage biotechnology company developing treatments for acute and chronic inner ear hearing loss, announced the completion of patient enrollment in its Phase 2 PROHEAR clinical study. ACOU085 (INN: Bimokalner) is a proprietary, first-in-class small molecule that has demonstrated robust and reproducible efficacy across multiple preclinical hearing loss models, including drug-induced ototoxicity. The PROHEAR Study is a double-blind, randomized, placebo-controlled, split-body, multicenter Phase 2 trial. It enrolled young male patients with metastatic testicular cancer who are scheduled to receive cisplatin-based chemotherapy. While cisplatin is a highly effective chemotherapeutic agent, cumulative doses of ≥300 mg/m² lead to clinically meaningful, permanent hearing loss in the majority of patients. Fifteen leading university hospitals in Germany are participating in this interdisciplinary study. Patients are randomized
Dr. Stefanie Kesting appointed as CEO of Thyssengas7.1.2026 14:06:26 CET | Press release
Dortmund, 06.01.2026 As of January 1, 2026, Dr. Stefanie Kesting has been appointed as the new Chief Executive Officer (CEO) of Thyssengas GmbH. She succeeds Dr. Thomas Gößmann, who will retire at the end of February 2026 after nearly nine years at the helm of the company. The leadership transition was announced in autumn 2025.
30 Years of European Spas: Nature, Natural Remedies and Climate Health as Europe’s Unique Strength7.1.2026 08:59:31 CET | Press release
To mark its 30th anniversary, the European Spas Association (ESPA) has released a special commemorative publication highlighting the strategic role of Europe’s medical spas and climate-health resorts in an era defined by prevention, longevity and sustainable wellbeing.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom

